Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 10, 2025TrialsOpen Access

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHong‐Hong YanGuy's and St Thomas' NHS Foundation TrustXHXin HuangSun Yat-sen UniversityPWPing WuUniversity of Electronic Science and Technology of China

Discussion

Loading...

Member takes

Overview

Prospective randomized trial compares efficacy and safety of ABC-14 regimen with traditional 3 + 7 in AML patients, suggesting improved treatment options.

Key Points

  • To compare the efficacy and safety of the ABC-14 regimen against traditional treatment approaches for newly diagnosed AML patients.
  • Prospective, multicenter, randomized, open-label clinical trial design
  • Participants include newly diagnosed acute myeloid leukemia (AML) patients
  • Interventions involve the ABC-14 regimen and traditional induction regimens
  • Evaluation of efficacy and safety outcomes between the ABC-14 and 3 + 7 regimens
  • Potential identification of superior treatment strategies for AML

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69401b262d562116f28f799ehttps://doi.org/10.1186/s13063-025-09339-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial2025
  2. 2The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience2025
  3. 3Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML2025
  4. 4Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia2026
  5. 5OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML2026 · 1 citations